Psychedelic Therapy for End-of-Life Distress

End-of-life anxiety, existential distress, and cancer-related depression are among the most compelling applications for psilocybin therapy. Landmark trials at NYU and Johns Hopkins demonstrated lasting reductions in anxiety and depression in cancer patients after a single psilocybin session — effects that persisted at 4.5-year follow-up. These results led directly to Oregon and Colorado including end-of-life care in their legal psilocybin programs.

17Clinical Trials

2Recruiting Now

0Companies

Several service centers in legal states now offer psilocybin therapy for patients facing terminal diagnoses or life-limiting illness. The FDA has granted Breakthrough Therapy Designation for psilocybin partly on the strength of end-of-life research, making it one of the closest indications to achieving formal regulatory recognition.

Evidence & Proven Benefits

What clinical research has shown for End-of-Life Distress, with citations to the studies behind each finding

Phase 2

Psilocybin reduced end-of-life depression and anxiety in cancer patients

In a randomized double-blind trial at Johns Hopkins, a single high dose of psilocybin produced large, sustained decreases in depression and anxiety in people with life-threatening cancer. At six months, about 78% showed a clinical response for depression and 83% for anxiety.

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trialGriffiths et al. — Journal of Psychopharmacology, 2016

Phase 2

Benefits persisted years after a single session

In the NYU cancer trial, a single psilocybin session produced rapid relief of anxiety and depression that remained evident at long-term follow-up years later — a durability rarely seen with conventional treatments.

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trialRoss et al. — Journal of Psychopharmacology, 2016

These summaries are for general education, not medical advice. Most psychedelic therapies remain investigational and are not yet approved — always consult a qualified clinician.